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Background: Nasal congestion is the main symptom of common cold. Symptomatic treatment 
with nasal decongestant seems to be the only treatment option. We conducted a study to 
assess the efficacy of Narlisim, a newly developed nasal spray, on nasal congestions in 
common cold. Materials and methods: Sixty adult patients with common cold were included 
in the study. Thirty patients were treated with Narlisim nasal spray, and 30 patients with 
isotonic nasal spray. The primary outcome was the assessment of the speed of relief of nasal 
congestion; the secondary outcome was the assessment of nasal congestion and nasal 
secretion symptoms by a 0–100% rating Visual analog score (VAS) scale on 5 items at 
baseline and after 5, 10, 15, 20, 25 and 30 minutes from treatment. Results: The study group 
experienced a faster relief of nasal congestion compared to the controlgroup151.1 vs 246.8 
seconds). VAS score progressively reduced for all investigated symptoms in both groups; a 
statistically significant higher mean reduction at each time point was recorded in the study 
group compared to controls (p<0.001). Conclusions: Our results suggest that Narlisim may 
be a promising medical device to control nasal congestion and rhinitis in common cold 
thanks to its nasal washing, hypertonic city, and low pH and osmo protection properties. 
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INTRODUCTION 
Flogosis of the nasal mucosa leads to 
swelling and prolonged congestion of 
nasal blood vessels during airflow nasal 
passage. Nasal congestion worsens 
breathing and leads to accumulation of 
thick nasal mucus with consequently 
“frequent desire to blow the nose”, “sleep 
disturbances”,” snoring” and “apnea”. For 
these reasons, Quality of Life in people 
affected by nasal congestion is low. Nasal 
congestion could be related to upper 
respiratory tract infections such as 
common cold or influenza, allergic 
rhinitis, sinus infection and chronic 





Common cold is one of the most prevalent 
causes of nasal congestion.Since there are 
no available therapies for common cold, 
symptomatic treatment with nasal 
decongestant seems to be the only 
treatment option [1]. 
 
Narlisim is a new nasal spray containing 
hhypertonic saline solution enriched with 
Pirometaxine, a combination between 
Pyrrolidone Carboxylic Acid (PCA) (4%) 
and Copper Sulphate (0.002%). Its 
mechanism of action consists in nasal 
washing, a decongestant effect, and the 
induction of a low pH environment to 
contrast virus and bacteria growth. 
 
In the present clinical trial we compared 
the effects of NARLISIM and isotonic 
saline in adults suffering from common 
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MATERIALS AND METHODS 
Data Collection and Study Design 
We conducted an Interventional Study 
Type (Clinical Trial) on 60 patients 
affected by nasal congestion secondary to 
common cold. The intervention model 
used in this open controlled clinical trial 
consisted of a parallel assessment. All 
patients gave their informed consent to the 
procedure. 
 
Patients aged ≥18 years visiting the 
outpatient service of the Otolaryngology 
Department “Lamezia Terme Hospital” 
and diagnosed with common cold between 
October 2017 and May 2018 were 
recruited. Patients’ assessment was based 
on accurate anamnestic investigation and a 
full ENT examination by the same team of 
specialists with nasal endoscopy. A 
diagnosis of common cold was based on 
self-reported symptoms, such as nasal 
obstruction and rhinorrhea, and nasal 
examination. Patients were asked to rank 
the severity of their subjective nasal 
congestion and secretion symptoms on a 
four-point scale (absent, slight, mild, 
severe). 
 
Patients were randomly allocated in 2 
groups: 30 patients were treated with the 
test reference at a dosage of two 
puffs/nostril/day (study group), and 30 
patients were treated with isotonic nasal 
spray (0.9% sodium chloride), with a 
dosage of two puffs/nostril/day (control 
group).Inclusion criteria were: 1) presence 
of common cold from less than 7 days; 2) 
subjective symptom ranking score of  2. 
Exclusion criteria were: 1) common cold 
or flu like symptoms for more than 7 days; 
2) hyper sensitivity or allergy to any 
component of the test product; 3) presence 
of a condition that could cause nasal 
obstruction such as severe nasal septal 
deviation or nasal polyposis; 4) previous 
nasal or sinus surgery; 5) recent 
assumption of drugs that may influence 
baseline symptom scores, such as nasal 
decongestants; 6) the subject is pregnant or 
lactating.  
Outcomes 
The primary outcome was the assessment 
of the speed of relief of nasal congestion 
(time after treatment administration). 
Subjects were instructed that the 
investigator would have administered two 
puffs of the nasal spray treatment into each 
nostril and then immediately start a stop 
clock. The subjects were asked to stop the 
clock when they feel any relief of nasal 
congestion. In case of no response; the 
clock was stopped after 10 minutes.  
 
The secondary outcome was the 
assessment of the symptoms of nasal 
congestion and nasal secretion by a 0–
100% rating Visual Analog Score (VAS) 
scale (0 = absence of symptoms; 
100%=completely present symptoms) on 5 
items: nasal obstruction, rhinorrhea, 
sneezing, lachrymation, nasal itching. This 
instrumental rating scale was administered 
before starting with test treatment and after 
5, 10, 15, 20, 25 and 30 minutes from 
treatment. 
 
Adverse events were documented by 
asking the subjects to record any signs and 
symptoms after treatment. Adverse events 
were recorded in the case report form at 
the final study visit. 
 
Analysis of data 
Statistical analysis was performed with 
Prism Graph Pad v7. The comparison of 
study group versus controls for sex was 
performed with Fisher’s exact test. The 
comparison of quantitative variables and 
scales in the two groups was performed 
with one-way analysis of variance with 
bootstrap. All tests were two tailed, and 




The research protocol of the study was 
discussed with and approved by the Ethics 




Thirty patients (11 males, 19 females; 
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Narlisim nasal spray and 30 patients (11 
males, 19 females; mean age: 35.5 years) 
with isotonic nasal physiological spray. 
There were no significant differences for 
age and gender between groups. The mean 
time of relief of nasal congestion was 
151.1 seconds in the study group and 246.8 
seconds in the control group. The difference 
between the groups was statistically 
significant (p<0.001) (Figure 1). 
 
 
Figure 1: Mean Time of the Achievement of Relief of Nasal Congestion between the Study 
and Control Group. 
 
Table 1: Mean Reduction of VAS Score From Nasal Spray Administration. 
Time After Administration of Nasal Spray 
(Minutes) 
Mean Reduction of Vas Score 
 Study Group Control Group 
5 28.4 15.3 
10 36 21.7 
15 38.7 21.7 
20 39.7 22.7 
25 39.7 25.3 
30 39.4 24 
 
The mean reduction of the VAS score after 
5 minutes was 28.4 points in the study 
group and 15.3 in the control group 
(p<0.001). VAS score progressively 
reduced for all investigated symptoms in 
both groups (Table 1) but showed a higher 
mean reduction with a statistically 
significant difference at each time point in 
the study group compared to 
controls(p<0.001). 
 
Figure 2 shows the mean reduction of 
VAS score after 10, 15, 20, 25 and 30 
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Figure 1: Visual analog score (VAS) score progressively reduced for all investigated 
symptoms in both groups; a statistically significant higher mean reduction at each time point 
was recorded in the study group compared to controls (p<0.001). 
 
No side effects to treatment, such as 
epistaxis or subjective discomfort, were 
recorded in both groups. 
 
DISCUSSION 
In the present paper we compared the 
effects of Narlisim, a nasal spray 
containing hypertonic saline solution 
enriched with pyrrolidone glutamic acid 
plus copper sulphate, and of isotonic nasal 
spray on nasal congestion and secretion 
symptoms in patients affected by common 
cold. Patients in the study group had a 
significantly faster relief of nasal 
congestion symptoms compared to 
controls.  
 
Common cold is a frequent condition in 
adults and children; on average, adults are 
affected 2.5 times/year leading to a loss of 
working days and reduced productivity. 
The cost of non-influenza-related viral 
upper respiratory tract infections is around 
US$40 billion annually [2].  
Nasal irrigation with hypertonic saline is 
commonly used to treat nasal congestion; 
the osmotic activities of hypertonic saline 
improve the mucociliary clearance, 
mechanically removes viruses and bacteria 
and improves nasal congestion. However, 
hypertonic saline solutions may not 
improve nasal symptoms or illness 
duration in patients with the common cold 
or rhino sinusitis [3-5]. 
 
Many nasal drugs have been proposed to 
treat nasal congestion. Oxymetazoline and 
xylometazoline are alpha-
sympathomimetics components of the 
nasal decongestant sprays; they have a 
rapid onset of action, but their effect 
decreases with repeated applications and 
leads to injuries to the nasal mucosa and 
alteration of the ciliary function [6, 7]. 
Antihistamines, intranasal corticosteroids, 
codeine, nasal saline irrigation, Echinacea 
angustifolia preparations, and steam 
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effective at relieving cold symptoms for 
adults [8]. Pseudoephedrine, 
phenylephrine, inhaled ipratropium, and 
zinc (acetate or gluconate) modestly 
reduce the severity and duration of 
symptoms for adults. Other drugs, such as 
non steroidalanti-inflammatory drugs, 
vitamin C and some herbal preparations, 
including Echinacea purpurea, have been 
shown to improve symptoms in adults.  
 
Considering the need for a new and safe 
local effective treatment for nasal 
congestion, a new nasal washing medical 
device containing Pirometaxine (Narlisim) 
has been developed and marketed in Italy. 
Pirometaxine, a new combination between 
PCA (4%) and Copper Sulphate (0.002%) 
adds to the well-known mechanical 
activities of nasal washing other peculiar 
and specific mechanical activities such 
ashypertoni city of the solution (2.4%) 
with consequent well known decongestant 
effect
9
 and low pH [10]. The latter is 
induced by PCA and, together with the 
local mechanical well known 
environmental restoring action of Copper 
Sulphate [11], creates a consequent “stress 
condition” for virus and bacteria of the 
upper respiratory airways. Rennie et al 
have previously demonstrated a reduction 
of the severity of Influenza-A Sydney/5/97 
virus with early application of low pH 
nasal sprays versus saline control [10], and 
virus inactivation studies showed that 
influenza viruses are rapidly inactivated by 
contact with acid buffered solutions at pH 
3.5 [10]. PCA has been universally 
recognized as compatible osmolytes with 
cellular osmoprotectant activities [10-12] 
thanks to its ability to trap water [13] so 
that its application directly in the nose 
could improve osmotic balance in the 
nasal mucosa. A retrospective 
observational study on children
 
confirmed 
the safety and the efficacy of NARLISIM 
spray to control nasal congestion, and 
other symptoms of common cold, in a 
short time period [14]. The combination of 
Narlisim with other drugs such as 
ibuprofen, paracetamol, or topical 
corticosteroids did not improve the 
outcome, thus suggesting the effectiveness 
of NARLISIM alone in the treatment of 
nasal congestion and common cold 
symptoms. This was further confirmed by 




Our results suggest that Pirometaxine nasal 
solution (Narlisim) may be a promising 
medical device to control nasal congestion 
and rhinitis in common cold thanks to its 
nasal washing, hypertonic city, and low 
pH and osmo protection properties. 
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